Following this, Sangsuwannukul et al. explored CAR T cells targeting CD133, and demonstrated that these cells can effectively eradicate CD133-expressing CCA cells, significantly increasing tumor cell lysis and enhancing key immune response cytokines IFN-γ and TNF-α [52]. This evidence concerns the gene PROM1 and cholangiocarcinoma.